HedgeChatter

  • Home /
  • Tag Archives

OXGN

OXiGENE Appoints Dai Chaplin, Ph.D., to Its Board of Directors

[at noodls] – SOUTH SAN FRANCISCO, Calif., Jan. 23, 2013 (GLOBE NEWSWIRE) — OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that David … moreView todays social media effects on OXGNView the latest stocks trending across Twitter. Click to view dashboardSee who OXiGENE is hiring next, click here to view […]

January 23, 2013 Bystocknews , Comments Off on OXiGENE Appoints Dai Chaplin, Ph.D., to Its Board of Directors read more

OXiGENE Announces Presentation of Encouraging OXi4503 Preclinical and Clinical Data in Acute Myelogenous Leukemia at American Society of Hematology Meeting

[at noodls] – SOUTH SAN FRANCISCO, Calif., Dec. 10, 2012 (GLOBE NEWSWIRE) — OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today that … moreView todays social media effects on OXGNView the latest stocks trending across Twitter. Click to view dashboardSee who OXiGENE is hiring next, click here to view […]

December 10, 2012 Bystocknews , Comments Off on OXiGENE Announces Presentation of Encouraging OXi4503 Preclinical and Clinical Data in Acute Myelogenous Leukemia at American Society of Hematology Meeting read more

OXiGENE Announces OXi4503 Granted Orphan Designation for Treatment of Acute Myelogenous Leukemia

[at noodls] – SOUTH SAN FRANCISCO, Calif., Nov. 21, 2012 (GLOBE NEWSWIRE) — OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that its … moreView todays social media effects on OXGNView the latest stocks trending across Twitter. Click to view dashboard […]

November 21, 2012 Bystocknews , Comments Off on OXiGENE Announces OXi4503 Granted Orphan Designation for Treatment of Acute Myelogenous Leukemia read more

OXiGENE Announces Phase 2 Data on ZYBRESTAT to Treat the Eye Disease, Polypoidal Choroidal Vasculopathy (PCV), Presented at the American Academy of Ophthalmology 2012 Annual Meeting

[at noodls] – SOUTH SAN FRANCISCO, Calif., Nov. 12, 2012 (GLOBE NEWSWIRE) — OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the presentation … moreView todays social media effects on OXGNView the latest stocks trending across Twitter. Click to view dashboard […]

November 12, 2012 Bystocknews , Comments Off on OXiGENE Announces Phase 2 Data on ZYBRESTAT to Treat the Eye Disease, Polypoidal Choroidal Vasculopathy (PCV), Presented at the American Academy of Ophthalmology 2012 Annual Meeting read more